Literature DB >> 15122206

The proteasome: a suitable antineoplastic target.

Julian Adams1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15122206     DOI： 10.1038/nrc1361

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  370 in total

1.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Authors:  David Y Chen; Yishan Lee; Brian A Van Tine; Adam C Searleman; Todd D Westergard; Han Liu; Ho-Chou Tu; Shugaku Takeda; Yiyu Dong; David R Piwnica-Worms; Kyoung J Oh; Stanley J Korsmeyer; Ann Hermone; Richard Gussio; Robert H Shoemaker; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2011-12-13       Impact factor: 12.701

Review 2.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

3.  Proteasome inhibitors suppress expression of NPM and ARF proteins.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 4.  Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.

Authors:  Min Shen; Tak Hang Chan; Q Ping Dou
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

5.  Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

Authors:  Hyun Joo Jung; Zheng Chen; Michael Wang; Luis Fayad; Jorge Romaguera; Larry W Kwak; Nami McCarty
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

Review 6.  Proteasome inhibitors in mantle cell lymphoma.

Authors:  Beata Holkova; Steven Grant
Journal:  Best Pract Res Clin Haematol       Date:  2012-05-16       Impact factor: 3.020

7.  A panel of subunit-selective activity-based proteasome probes.

Authors:  Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Boudewijn A Duivenvoorden; Gijsbert A van der Marel; Bogdan I Florea; Alexei F Kisselev; Herman S Overkleeft
Journal:  Org Biomol Chem       Date:  2010-05-06       Impact factor: 3.876

Review 8.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

Review 9.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

10.  26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors.

Authors:  Ingrid Gerke; Franz-Josef Kaup; Stephan Neumann
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.